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Evaluation of novel CEX resin for continuous
processing of Mab purification
Takuya Muramoto, Ph. D
Bio-manufacturing Technology Laboratories, CMC center

Abstract
• We have evaluated novel cation exchange resin and membrane which is potentially suited for continuous
process in biologics manufacturing.
• Typically cation exchange chromatography (CEX) is used in a bind/elute (B/E) mode for the MAb process
since MAb act as cation at the buffer condition used for CEX due to the pI from neutral to weak basic.
Generally, purpose of CEX chromatography is to remove aggregates and other impurities like HCP and
DNA. Especially, aggregate removal is of interest to the industries. A continuous process in MAb
downstream process can solve several bottlenecks in typical batch process. However its capability cannot
be fully utilized if some step of chromatography is used in a B/E mode since it will take a longer process
time due to the posing of product stream for binding and washing and it will take a more cost due to the
requirement of large amount of resins as we use at the batch process. In such a case, chromatography in
flowthrough mode has a potential to overcome those issues for both cost and time and enables us to
develop more streamlined continuous process.
• We will present the result of our study to evaluate novel CEX resin developed by EMD Millipore (The Life
Science division of Merck KGaA, Darmstadt, Germany) by comparing with the existing process of Mab A
and we obtained a conclusion that this resin is fitted to the continuous processing very much. The novel
resin showed a better impurity clearance than our existing process. For example, over 65% removal of
aggregate by the novel resin was obtained in contrast to no removal by the existing process. A 20-fold
better clearance for DNA was confirmed for the novel resin than the existing process. This indicates an
additional polishing step can be omitted and this new chromatography can be a strong option if we
need to reduce such impurities further. Also the resin cost is expected to be reduced down to 1/10 in
maximum since those impurity clearance results were obtained about 10-times larger load than the
typical B/E mode operation of CEX. Considering those aspects, we conclude that this resin showed a
better fit for a continuous process. We will also discuss an expected effect of the novel CEX resin on cost
and process time savings by a continuous process.
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Background
Monoclonal antibody purification platform
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• Typically in mAb purification process, CEX
chromatography is operated in bind/elute
mode due to the isoelectric point of mAb
(pI 7-9).
• CEX removes aggregates, fragments, and
HCP efficiently.
• Recently, CEX resin for flow/through
mode has been developed in some
companies.
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CEX Flow/through technology
 Bind impurities
Smaller volume of resin or membrane
(HCP, DNA, Aggregate)
Single-use compliant
 Less steps
"Green" process
(no wash, elution step)
Less process development needed
Less buffer number (fewer steps)
Reduced buffer consumption
 Easily applicable to continuous processing
CEX  AEX  Virus filtration (tank less, hold less)
Processing time and in-process holding tanks can be reduced
Smaller column can be used
 Evaluation of novel CEX adsorber
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Chromatogram of novel CEX resin
Column volume: 1mL (0.8 cm ID x 2 cm H)
Load sample: Mab A CEX Load 25 mg/mL (2-fold dilution according to conditions
vendor recommended, pH5, 3.2 mS/cm )
Load amount: 1300 mg/mL-resin
Flow rate: 0.33 mL/min (Residence time: 3 min)

Equilibration
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Flow through
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Impurity removal property
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• Efficient reduction of impurities was observed as the manufacturer's information.
• Aggregates and Fragments gradually increased as amount of load. However, significant
breakthrough of impurities was not observed under the tested condition.
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SEC analysis
Load, Flow through Pool, Strip sample
Load

Load:
Flow through:
Strip:
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Flow through Pool

98.9% monomer, 0.3% HMW, 0.8% LMW
99.1% monomer, 0.06% HMW, 0.9% LMW
94.5% monomer, 4.0% HMW, 1.5% LMW

Strip

Comparison of CEX Bind/Elute mode and Flow/through mode
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Summary
• Impurity removal capability by novel CEX F/T resin was comparable or better
than by current CEX process with vendor-recommended conditions as the
first evaluation.
• Resin volume can be reduced for about 1/10
 Current CEX process is operated in Bind/Elute mode with Capacities < 100
g/L-resin. Merck CEX resin is operated in Flowthrough mode with
Capacities > 1000 g/L, which allows for a smaller CEX column (up to 90%
reduction)
 For example, 60 cm ID x 20 cm  20 cm ID x 20 cm

• Reduce buffer number and fluid volume depending on column size
Lower costs and save process time in CEX process can be achieved.
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Future plan
 Optimize sample loading condition (pH, conductivity, flowrate, etc.)
 Continue to explore further candidates for CEX F/T mode
 Application to continuous processing
 Coupling of CEX and AEX step
 Buffer selection which is suitable for in-line conditioning (pH and conductivity)
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